GlassScriptPhysician profile
Thomas J Vasdekas
NPI 1275630253
$100,939.75
in general payments reported to CMS, 2019-2025
23 companies · $6,248 in 2025
The $6,248 reported for 2025 was more than what 92% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $26K · 2021: $28K · 2022: $13K · 2023: $85.74 · 2024: $666 · 2025: $6,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,893 · Travel and Lodging: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,892.57 |
| Travel and Lodging | $1,107.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $99,021.76 | 2019-2025 | |
| Baxter Healthcare | $503.87 | 2024-2025 | Perclot, Floseal, Tisseel |
| Davol INC. | $460.17 | 2019-2025 | Phasix Mesh |
| Kerecis Limited | $177.42 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Conmed Corporation | $92.83 | 2022-2025 | Airseal |
| Smith+Nephew, INC. | $91.59 | 2022-2025 | Stravix, Stravix Pl |
| Sirius Medical Systems | $80.10 | 2024 | Pintuition |
| Medtronic, INC. | $77.75 | 2024 | Ligasure |
| Tela Bio, INC. | $66.38 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Takeda Pharmaceuticals U.S.A., INC. | $55.56 | 2020-2022 | |
| Tei Biosciences INC | $43.18 | 2019 | |
| Innocoll Pharmaceuticals Limited | $41.98 | 2022 | |
| Stryker Corporation | $36.89 | 2024 | 1788 |
| Allergan, INC. | $30.17 | 2020 | |
| Ethicon US, LLC | $26.68 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $20.75 | 2019 | |
| Medtronic USA, INC. | $20.10 | 2020 | |
| Merck Sharp & Dohme LLC | $19.92 | 2023 | Keytruda |
| Myriad Genetic Laboratories, INC. | $18.09 | 2025 | Myrisk |
| Heron Therapeutics, INC. | $17.79 | 2024 | Aponvie |
| Shire North American Group INC | $12.95 | 2019 | |
| Baudax Bio INC. | $12.39 | 2021 | |
| W. L. Gore & Associates, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Vasdekas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.